CHIA-CHI LINCHIH-HUNG HSUCHIA-HSIEN CHENGHSIU-PO WANGJANG-MING LEEKUN-HUEI YEHCHIH-HSIN YANGLin J.-T.ANN-LII CHENGLee Y.-C.2020-03-312020-03-3120070923-7534https://www.scopus.com/inward/record.uri?eid=2-s2.0-33846484324&doi=10.1093%2fannonc%2fmdl339&partnerID=40&md5=2ee1ceef9782b486e32ed55202822a25https://scholars.lib.ntu.edu.tw/handle/123456789/481643Background: To test the feasibility of incorporating a twice-weekly paclitaxel (Taxol) and cisplatin regimen into concurrent chemoradiotherapy (CCRT), followed by surgery, for patients with locally advanced esophageal cancer. Patients and methods: Patients with operable T3N0-1M0 or T1-3N1M0 esophageal cancer were enrolled. The CCRT regimen included paclitaxel (35 mg/m2 1 h on days 1 and 4/week), cisplatin (15 mg/m2 1 h on days 2 and 5/week), and radiotherapy (2 Gy on days 1-5/week). When the accumulated radiation dose reached 40 Gy, the feasibility of esophagectomy was evaluated in all patients. In patients for whom esophagectomy was not feasible, CCRT was continued to a dose of 60 Gy. Results: The majority of 97 patients enrolled had squamous cell carcinoma on histology (95%) and T3N1 disease by endoscopic ultrasonographic staging (90%). All patients received CCRT to 40 Gy. Sixty-one patients underwent surgery, and 26 patients continued definitive CCRT to 60 Gy. The intention-to-treat pathological complete response rate was 25% [24/97, 95% confidence interval (CI) 16-33]. At a median follow-up of 25.3 months, the median progression-free and overall survival was 15.6 and 28.8 months, respectively. The most common grade 3/ 4 toxic effects were leukopenia (30%), thrombocytopenia (10%), and diarrhea (15%). Conclusions: CCRT with a twice-weekly paclitaxel and cisplatin regimen followed by esophagectomy is an active treatment of locally advanced esophageal cancer. ? 2007 Oxford University Press.[SDGs]SDG3antiemetic agent; cisplatin; dexamethasone; diphenhydramine; paclitaxel; ranitidine; adult; advanced cancer; aged; alanine aminotransferase blood level; anastomosis leakage; anemia; article; blood toxicity; cancer adjuvant therapy; cancer radiotherapy; cancer staging; cancer survival; clinical trial; confidence interval; controlled clinical trial; controlled study; creatinine blood level; diarrhea; drug dose reduction; drug fatality; drug fever; drug hypersensitivity; drug response; drug withdrawal; endoscopic echography; esophageal adenocarcinoma; esophageal squamous cell carcinoma; esophagitis; esophagus cancer; esophagus resection; feasibility study; female; follow up; histopathology; human; infection; leukopenia; liver failure; major clinical study; male; neutropenia; phase 2 clinical trial; priority journal; radiation dose; respiratory failure; sensory neuropathy; side effect; stomatitis; survival rate; thrombocytopenia; tumor bleeding; vomiting; Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Combined Modality Therapy; Esophageal Neoplasms; Esophagectomy; Feasibility Studies; Female; Fluorouracil; Follow-Up Studies; Humans; Male; Middle Aged; Survival Ratejournal article10.1093/annonc/mdl339170282442-s2.0-33846484324